Le Lézard
Classified in: Health, Science and technology, Business
Subjects: ERN, ERP

Accelerate Diagnostics Reports Second Quarter 2022 Financial Results


TUCSON, Ariz., Aug. 15, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2022.

"In addition to a solid quarter, I am pleased to announce that we will be joining forces with Becton Dickinson to commercialize our products globally," commented Jack Phillips, Chief Executive Officer of Accelerate Diagnostics, Inc.  "Our global commercial partnership with BD comes at a time when the hospital selling environment is improving, we are firing on all cylinders in R&D and are taking meaningful steps to improve our balance sheet.  These are exciting times for our company."

Second Quarter 2022 Highlights

Year-to-date 2022 Highlights

Full financial results for the quarter ending June 30, 2022 will be filed on Form 10-Q through the Securities and Exchange Commission's (SEC) website at http://www.sec.gov.

Audio Webcast and Conference Call

To listen to the 2022 second quarter financial results, call by phone, +1.877.883.0383 and enter Elite Entry Number: 8181593. International participants may dial +1.412.902.6506. Please dial in 10?15 minutes prior to the start of the conference. A replay of the call will be available by telephone at +1.877.344.7529 (U.S.) or +1.412.317.0088 (International) using the replay code 5773022 until September 6, 2022.

This conference call will also be webcast and can be accessed from the company's website at ir.axdx.com. A replay of the audio webcast will be available until November 15, 2022.

Use of Non-GAAP Financial Measures

This press release contains certain financial measures that are not recognized measures under accounting principles generally accepted in the United States of America ("GAAP"), which include SG&A, R&D, and Net income (loss) amounts excluding stock-based compensation expenses. 

Our management and board of directors use expenses excluding the cost of stock-based compensation to understand and evaluate our operating performance and trends, to prepare and approve our annual budget and to develop short-term and long-term operating and financing plans. Accordingly, we believe that expenses excluding the cost of stock-based compensation provides useful information for investors in understanding and evaluating our operating results in the same manner as our management and our board of directors. Expenses excluding the cost of stock-based compensation is a non-GAAP financial measure and should be considered in addition to, not as superior to, or as a substitute for, SG&A expenses, R&D expenses, and net income (loss) reported in accordance with GAAP. The following tables present a reconciliation of SG&A expenses, R&D expenses and net income (loss) excluding stock-based compensation to comparable GAAP measures for the periods indicated:


Three Months Ended June 30,

Six Months Ended June 30,


(in thousands)

(in thousands)


2022

2021

2022

2021

Sales, General and Administrative

$         11,493

$        12,910

$         22,167

$         26,938

Non-cash equity-based compensation as a component of sales, general and administrative

3,204

5,188

5,646

11,180

Sales, general and administrative less non-cash equity-based compensation

$           8,289

$          7,722

$         16,521

$         15,758





Three Months Ended June 30,

Six Months Ended June 30,


(in thousands)

(in thousands)


2022

2021

2022

2021

Research and Development

$                7,576

$               5,733

$              13,600

$              12,629

Non-cash equity-based compensation as a component of research and development

539

1,328

901

4,074

Research and development less non-cash equity-based compensation

$                7,037

$               4,405

$              12,699

$                8,555







Three Months Ended June 30,

Six Months Ended June 30,


(in thousands)

(in thousands)


2022

2021

2022

2021

Loss from operations

$             (17,989)

$            (17,590)

$             (33,884)

$             (37,616)

Non-cash equity-based compensation as a component of loss from operations

3,971

6,590

6,950

15,429

Loss from operations less non-cash equity-based compensation

$             (14,018)

$            (11,000)

$             (26,934)

$             (22,187)






About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1?2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.

The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.

For more information about the company, its products and technology, or recent publications, visit axdx.com.

Forward-Looking Statements

Certain of the statements made in this press release are forward looking or may have forward looking implications, such as, among others, Mr. Phillip's statements regarding the hospital selling environment improving and the productivity of our research and development activities. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned "Risk Factors" in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 14, 2022, and in any other reports that the company files with the Securities and Exchange Commission. The company's forward-looking statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.

 

ACCELERATE DIAGNOSTICS, INC.

CONDENSED CONSOLIDATED

BALANCE SHEETS

(in thousands, except share data)



June 30,

December 31,


2022

2021


Unaudited


ASSETS

Current assets:



Cash and cash equivalents

$4,581

$39,898

Investments

32,191

23,720

Trade accounts receivable, net

2,935

2,320

Inventory

5,304

5,067

Prepaid expenses

1,429

768

Other current assets

1,619

1,558

Total current assets

48,059

73,331

Property and equipment, net

4,097

5,389

Finance lease assets, net

2,538

?

Operating lease right of use assets, net

2,181

2,510

Other non-current assets

1,851

1,817

Total assets

$58,726

$83,047

LIABILITIES AND STOCKHOLDERS' DEFICIT

Current liabilities:



Accounts payable

$2,221

$1,983

Accrued liabilities

5,654

2,853

Accrued interest

746

909

Deferred revenue

335

451

Current portion of long-term debt

84

80

Finance lease, current

953

?

Operating lease, current

732

669

Total current liabilities

10,725

6,945

Finance lease, non-current

1,383

?

Operating lease, non-current

1,997

2,381

Other non-current liabilities

757

808

Convertible notes

105,828

107,984

Total liabilities

$120,690

$118,118




Commitments and contingencies






Stockholders' deficit:



Preferred shares, $0.001 par value;



5,000,000 preferred shares authorized and 3,954,546 outstanding as of June 30, 2022 and December 31, 2021

4

4

Common stock, $0.001 par value;



200,000,000 common shares authorized with 79,701,428 shares issued and outstanding on June 30, 2022 and 100,000,000 common shares authorized with 67,649,018 shares issued and outstanding on December 31, 2021

80

68

Contributed capital

560,185

580,652

Treasury stock

(45,067)

(45,067)

Accumulated deficit

(576,734)

(570,668)

Accumulated other comprehensive loss

(432)

(60)

Total stockholders' deficit

(61,964)

(35,071)

Total liabilities and stockholders' deficit

$58,726

$83,047

See accompanying notes to condensed consolidated financial statements.

ACCELERATE DIAGNOSTICS, INC.

CONDENSED CONSOLIDATED

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

Unaudited

(in thousands, except per share data)



Three Months Ended


Six Months Ended


June 30,

June 30,


June 30,

June 30,


2022

2021


2022

2021

Net sales

$3,861

$2,798


$6,820

$5,316







Cost of sales

2,781

1,745


4,937

3,365

Gross profit

1,080

1,053


1,883

1,951







Costs and expenses:






Research and development

7,576

5,733


13,600

12,629

Sales, general and administrative

11,493

12,910


22,167

26,938

Total costs and expenses

19,069

18,643


35,767

39,567







Loss from operations

(17,989)

(17,590)


(33,884)

(37,616)







Other income (expense):






Interest expense

(713)

(4,177)


(1,630)

(8,267)

Gain on extinguishment of debt

919

?


3,565

?

Foreign currency exchange gain (loss)

31

?


40

(159)

Interest income

56

12


78

55

Other (expense) income, net

(107)

81


(157)

74

Total other income (expense), net

186

(4,084)


1,896

(8,297)







Net loss before income taxes

(17,803)

(21,674)


(31,988)

(45,913)

Provision for income taxes

?

?


?

?

Net loss

$(17,803)

$(21,674)


$(31,988)

$(45,913)







Basic and diluted net loss per share

$(0.23)

$(0.36)


$(0.44)

$(0.77)

Weighted average shares outstanding

76,231

61,049


71,998

59,790







Other comprehensive loss:






Net loss

$(17,803)

$(21,674)


$(31,988)

$(45,913)

Net unrealized (loss) gain on debt securities available-for-sale

(39)

1


(132)

(18)

Foreign currency translation adjustment

(161)

21


(240)

(60)

Comprehensive loss

$(18,003)

$(21,652)


$(32,360)

$(45,991)

See accompanying notes to condensed consolidated financial statements.

ACCELERATE DIAGNOSTICS, INC.

CONDENSED CONSOLIDATED

STATEMENTS OF CASH FLOWS

Unaudited

(in thousands)



Six Months Ended


June 30,

June 30,


2022

2021

Cash flows from operating activities:



Net loss

$(31,988)

$(45,913)

Adjustments to reconcile net loss to net cash used in operating activities:



Depreciation and amortization

1,435

1,248

Amortization of investment discount

79

97

Equity-based compensation

6,950

15,429

Amortization of debt discount and issuance costs

284

6,079

Loss (gain) on disposal of property and equipment

283

(100)

Unrealized loss on equity investments

157

?

Gain on extinguishment of debt

(3,565)

?

(Increase) decrease in assets:



Contributions to deferred compensation plan

(110)

(236)

Accounts receivable

(615)

(564)

Inventory

(416)

(524)

Prepaid expense and other

(719)

60

Increase (decrease) in liabilities:



Accounts payable

658

564

Accrued liabilities

2,288

736

Accrued interest

(159)

45

Deferred revenue and income

(116)

(94)

Deferred compensation

(51)

245

Net cash used in operating activities

(25,605)

(22,928)




Cash flows from investing activities:



Purchases of equipment

(447)

(29)

Purchase of marketable securities

(27,504)

(15,699)

Maturities of marketable securities

18,738

23,993

Net cash (used in) provided by investing activities

(9,213)

8,265




Cash flows from financing activities:



Proceeds from issuance of common stock

?

22,122

Payments on finance leases

(424)

?

Proceeds from exercise of options

7

1,222

Proceeds from issuance of common stocks under employee purchase plan

137

161

Net cash (used in) provided by financing activities

(280)

23,505




Effect of exchange rate on cash

(219)

(43)




(Decrease) increase in cash and cash equivalents

(35,317)

8,799

Cash and cash equivalents, beginning of period

39,898

35,781

Cash and cash equivalents, end of period

$4,581

$44,580

See accompanying notes to condensed consolidated financial statements.

ACCELERATE DIAGNOSTICS, INC.

CONDENSED CONSOLIDATED

STATEMENTS OF CASH FLOWS (CONTINUED)

Unaudited

(in thousands)



Six Months Ended


June 30,

June 30,


2022

2021

Non-cash investing activities:



Net transfer of instruments from inventory to property and equipment

$202

$500

Supplemental cash flow information:



Interest paid

$1,506

$2,144

Extinguishment of Convertible Senior Notes through issuance of common stock

$10,180

$?

See accompanying notes to condensed consolidated financial statements.

 

SOURCE Accelerate Diagnostics, Inc.


These press releases may also interest you

at 07:48
HAPPE Spine announces the addition of two more issued patents in a growing portfolio establishing HAPPE as the leader of next generation orthopaedic and spinal implants enabled by the HAPPEtm (HydroxyApatite Porous PolyEtheretherketone) platform. The...

at 07:40
Massive Bio, a leader in AI-powered cancer clinical trial enrollment, announced a strategic partnership with Perthera.ai, a pioneer in connecting oncologists and patients with biomarker-based therapy options. Perthera.ai's patented ranked therapy...

at 07:31
A daily intake of a new dietary supplement (Nasafytol®) containing an oral combination of Quercetin (65 mg), Curcumin (42 mg) and Vitamin D3 (2.2 µg) for 14 days by early-stage mild to moderately symptomatic COVID-19 outpatients, resulted in more...

at 07:30
Areteia Therapeutics announces two key leadership appointments: Dr. Eric Bradford M.D. as Chief Medical Officer and Robin Walker J.D. as Chief Legal Officer and Corporate Secretary. These appointments report to Jorge Bartolome, CEO of Areteia...

at 07:30
Endo International plc  announced today the launch of its new branded video series, Coffee & Cords, which aims to educate people about Dupuytren's...

at 07:30
Numinus Wellness Inc. ("Numinus" or the "Company") , a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that its research division, Numinus Bioscience, has developed...



News published on 15 august 2022 at 08:15 and distributed by: